| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 80, 829-835, Copyright © 1995 by Endocrine Society
ARTICLES |
C Ferri, V Pittoni, A Piccoli, O Laurenti, MR Cassone, C Bellini, G Properzi, G Valesini, G De Mattia and A Santucci
University La Sapienza, Institute of I Clinica Medica, Andrea Cesalpino Foundation, Rome, Italy.
Endothelin-1 (ET-1) is a potent vasoactive and mitogenic peptide produced by the vascular endothelium. In this study, we evaluated whether insulin stimulates ET-1 secretion by human endothelial cells derived from umbilical cord veins and by human permanent endothelial hybrid cells Ea.hy 926. Moreover, to provide evidence that insulin may stimulate ET-1 secretion in vivo, plasma ET-1 levels were evaluated in 7 type II diabetic normotensive males (mean age, 54.3 +/- 4.0 yr) during 2-h hyperinsulinemic euglycemic clamps (287 pmol insulin/m2.min- 1) as well as in 12 obese hypertensive males (mean age, 44.2 +/- 4.6 yr) before and after a 12-week period of caloric restriction. Our results showed that insulin stimulated ET-1 release from cultured endothelial cells in a dose-dependent fashion. ET-1 release persisted for 24 h and was also observed at physiological insulin concentrations (10(-9) mol/L). The insulin-induced ET-1 secretion was inhibited by genistein, a tyrosine kinase inhibitor, and by cycloheximide, a protein synthesis inhibitor, suggesting that it requires de novo protein synthesis rather than ET-1 release from intracellular stores. In the in vivo experiments, plasma ET-1 levels rapidly increased during euglycemic hyperinsulinemic clamps (from 0.76 +/- 0.18 pg/mL at time zero to 1.65 +/- 0.21 pg/mL at 60 min; P < 0.05) and persisted elevated until the end of insulin infusion (1.37 +/- 0.37 pg/mL at 120 min; P < 0.05 vs. time zero). In obese hypertensives, plasma ET-1 levels significantly decreased after 12 weeks of caloric restriction (from 0.85 +/- 0.51 to 0.48 +/- 0.28 pg/mL; P < 0.04). The decrease in body weight induced by caloric restriction was accompanied by a significant reduction in fasting insulin levels (from 167.2 +/- 94.0 to 98.9 +/- 44.9 pmol/L; P < 0.05) which correlated with the reduction in plasma ET- 1 levels (r = 0.78; P < 0.003). In conclusion, our data show that insulin stimulates both in vitro and in vivo ET-1 secretion. Such interaction could play a significant role in the development of atherosclerotic lesions in hyperinsulinemic conditions.
This article has been cited by other articles:
 |
|
 |
|
  A. A. Lteif, A. D. Fulford, R. V. Considine, I. Gelfand, A. D. Baron, and K. J. Mather Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humans Am J Physiol Endocrinol Metab, December 1, 2008; 295(6): E1510 - E1517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ahlborg, A. Shemyakin, F. Bohm, A. Gonon, and J. Pernow Dual Endothelin Receptor Blockade Acutely Improves Insulin Sensitivity in Obese Patients With Insulin Resistance and Coronary Artery Disease Diabetes Care, March 1, 2007; 30(3): 591 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Sarafidis and G. L. Bakris Insulin and Endothelin: An Interplay Contributing to Hypertension Development? J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 379 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Potenza, F. L. Marasciulo, M. Tarquinio, M. J. Quon, and M. Montagnani Treatment of Spontaneously Hypertensive Rats With Rosiglitazone and/or Enalapril Restores Balance Between Vasodilator and Vasoconstrictor Actions of Insulin With Simultaneous Improvement in Hypertension and Insulin Resistance Diabetes, December 1, 2006; 55(12): 3594 - 3603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Potenza, F. L. Marasciulo, D. M. Chieppa, G. S. Brigiani, G. Formoso, M. J. Quon, and M. Montagnani Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H813 - H822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Orio Jr., S. Palomba, T. Cascella, B. De Simone, S. Di Biase, T. Russo, D. Labella, F. Zullo, G. Lombardi, and A. Colao Early Impairment of Endothelial Structure and Function in Young Normal-Weight Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4588 - 4593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cardillo, U. Campia, M. Iantorno, and J. A. Panza Enhanced Vascular Activity of Endogenous Endothelin-1 in Obese Hypertensive Patients Hypertension, January 1, 2004; 43(1): 36 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Treiber, P. Barbeau, G. Harshfield, H.-S. Kang, D. M. Pollock, J. S. Pollock, and H. Snieder Endothelin-1 Gene LYS198ASN Polymorphism and Blood Pressure Reactivity Hypertension, October 1, 2003; 42(4): 494 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Creager, T. F. Luscher, F. Cosentino, and J. A. Beckman Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I Circulation, September 23, 2003; 108(12): 1527 - 1532. [Full Text] [PDF]
|
|
|
|
|
|
A. Nohria, L. Garrett, W. Johnson, S. Kinlay, P. Ganz, and M. A. Creager Endothelin-1 and Vascular Tone in Subjects With Atherogenic Risk Factors Hypertension, July 1, 2003; 42(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Laakso and J. Kuusisto Diabetology for cardiologists Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B5 - B13. [Abstract] [PDF]
|
|
|
|
|
|
K. J. Mather, B. Mirzamohammadi, A. Lteif, H. O. Steinberg, and A. D. Baron Endothelin Contributes to Basal Vascular Tone and Endothelial Dysfunction in Human Obesity and Type 2 Diabetes Diabetes, December 1, 2002; 51(12): 3517 - 3523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Eringa, C. D.A. Stehouwer, T. Merlijn, N. Westerhof, and P. Sipkema Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles Cardiovasc Res, December 1, 2002; 56(3): 464 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cardillo, U. Campia, M. B. Bryant, and J. A. Panza Increased Activity of Endogenous Endothelin in Patients With Type II Diabetes Mellitus Circulation, October 1, 2002; 106(14): 1783 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Okafor, P. Mukhopadhyay, and N. A. Delamere Studies on Endothelin Release and Na,K Transport in Porcine Lens Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 790 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Bagg, C. Ferri, G. Desideri, G. Gamble, P. Ockelford, and G. D. Braatvedt The Influences of Obesity and Glycemic Control on Endothelial Activation in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5491 - 5497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Galipeau, E. Arikawa, I. Sekirov, and J. H. McNeill Chronic Thromboxane Synthase Inhibition Prevents Fructose-Induced Hypertension Hypertension, October 1, 2001; 38(4): 872 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Monti, S. Allibardi, P. M. Piatti, G. Valsecchi, S. Costa, G. Pozza, S. Chierchia, and M. Samaja Triglycerides impair postischemic recovery in isolated hearts: roles of endothelin-1 and trimetazidine Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1122 - H1130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Misurski, S.-Q. Wu, J. R. McNeill, T. W. Wilson, and V. Gopalakrishnan Insulin-Induced Biphasic Responses in Rat Mesenteric Vascular Bed : Role of Endothelin Hypertension, May 1, 2001; 37(5): 1298 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Desideri, A. Gaspardone, M. Gentile, A. Santucci, P. A. Gioffre, and C. Ferri Endothelial Activation in Patients With Cardiac Syndrome X Circulation, November 7, 2000; 102(19): 2359 - 2364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Luscher and M. Barton Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs Circulation, November 7, 2000; 102(19): 2434 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Claxton, M. W. Brands, S. M. Fitzgerald, and J. A. Cameron Inhibition of Nitric Oxide Synthesis Potentiates Hypertension During Chronic Glucose Infusion in Rats Hypertension, January 1, 2000; 35(1): 451 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kashiwagi, K. Shinozaki, Y. Nishio, H. Maegawa, Y. Maeno, A. Kanazawa, H. Kojima, M. Haneda, H. Hidaka, H. Yasuda, et al. Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats Am J Physiol Endocrinol Metab, December 1, 1999; 277(6): E976 - E983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cardillo, S. S. Nambi, C. M. Kilcoyne, W. K. Choucair, A. Katz, M. J. Quon, and J. A. Panza Insulin Stimulates Both Endothelin and Nitric Oxide Activity in the Human Forearm Circulation, August 24, 1999; 100(8): 820 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tiret, O. Poirier, V. Hallet, T. A. McDonagh, C. Morrison, J. J. V. McMurray, H. J. Dargie, D. Arveiler, J.-B. Ruidavets, G. Luc, et al. The Lys198Asn Polymorphism in the Endothelin-1 Gene Is Associated With Blood Pressure in Overweight People Hypertension, May 1, 1999; 33(5): 1169 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Rossi, S. Colonna, E. Pavan, G. Albertin, F. Della Rocca, G. Gerosa, D. Casarotto, S. Sartore, P. Pauletto, and A. C. Pessina Endothelin-1 and Its mRNA in the Wall Layers of Human Arteries Ex Vivo Circulation, March 9, 1999; 99(9): 1147 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J Rabelink, E. S.G Stroes, K.P. Bouter, and P. Morrison Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease? Cardiovasc Res, September 1, 1998; 39(3): 543 - 549. [Full Text] [PDF]
|
|
|
|
|
|
D. Hasdai, D. R. Holmes Jr., D. M. Richardson, U. Izhar, and A. Lerman Insulin and IGF-I attenuate the coronary vasoconstrictor effects of endothelin-1 but not of sarafotoxin 6c Cardiovasc Res, September 1, 1998; 39(3): 644 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.M. Piatti, L.D. Monti, G. Valsecchi, M. Conti, R. Nasser, B. Guazzini, E. Fochesato, C.V. Phan, A.E. Pontiroli, and G. Pozza Effects of Low-Dose Heparin Infusion on Arterial Endothelin-1 Release in Humans Circulation, December 1, 1996; 94(11): 2703 - 2707. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Xiong, H. Tanaka, J. A. Richardson, S. C. Williams, C. A. Slaughter, M. Nakamura, J.-L. Chen, and M. Yanagisawa Endothelin-1 Stimulates Leptin Production in Adipocytes J. Biol. Chem., July 20, 2001; 276(30): 28471 - 28477. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
